MozartV1, France, Analysis, bibRecord, 000106

Bioavailability of melatonin in humans after day‐time administration of D7 melatonin

Identifieur interne : 000106 ( France/Analysis ); précédent : 000105; suivant : 000107

Bioavailability of melatonin in humans after day‐time administration of D7 melatonin

Auteurs : J. B. Fourtillan [France] ; A. M. Brisson [France] ; P. Gobin [France] ; I. Ingrand [France] ; J. Ph. Decourt [France] ; J. Girault [France]

Source :

Biopharmaceutics & Drug Disposition [ 0142-2782 ] ; 2000-01.

RBID : ISTEX:20DC831A3C9C35916E1C0A23339D91E80544CD5E

English descriptors

KwdEn :
- Administration, Oral, Adult, Anticonvulsants (administration & dosage), Anticonvulsants (blood), Anticonvulsants (pharmacokinetics), Area Under Curve, Biological Availability, Cross-Over Studies, D7 melatonin, Female, Gas Chromatography-Mass Spectrometry, Humans, Infusions, Intravenous, Male, Melatonin (administration & dosage), Melatonin (blood), Melatonin (pharmacokinetics), Metabolic Clearance Rate, Time Factors, bioavailability, pharmacokinetics, young healthy subjects.
MESH :
- chemical , administration & dosage : Anticonvulsants, Melatonin.
- chemical , blood : Anticonvulsants, Melatonin.
- chemical , pharmacokinetics : Anticonvulsants, Melatonin.
- Administration, Oral, Adult, Area Under Curve, Biological Availability, Cross-Over Studies, Female, Gas Chromatography-Mass Spectrometry, Humans, Infusions, Intravenous, Male, Metabolic Clearance Rate, Time Factors.

Abstract

Absolute bioavailability of the neurohormone melatonin (MLT) was studied in 12 young healthy volunteers (six males, six females) after administration at midday, on two separate occasions, of 23 µg by intravenous (i.v.) infusion and 250 µg by oral solution of D7 MLT, a molecule in which seven deuterium atoms replace seven hydrogen atoms. Exogenous (D7) and endogenous (D0) MLT were quantified simultaneously but separately by a highly specific assay: gas chromatography/negative ion chemical ionization mass spectrometry, developed in our laboratory, which enabled us to go down to 0.5 pg/mL in plasma samples. After i.v. administration, the maximum plasma concentration (Cmax) and the area under the plasma concentration–time curve (AUC) values were significantly different in male and female subjects, but there was no significant gender difference in total body clearance normalized to body weight: 1.27±0.20 L/h/kg and 1.18±0.22 L/h/kg for males and females, respectively. The apparent terminal half‐life (t 1/2 z) values were 36±2 and 41±10 min, respectively. After oral administration, pharmacokinetic parameters used to quantify bioavailability were near three‐fold greater in female subjects than in males, with large inter‐individual variations. The maximum plasma MLT concentration Cmax±S.D. was found at 243.7±124.6 pg/mL and 623.6±575.1 pg/mL for male and female subjects respectively, while the mean values for AUCs were 236±107 pg.h/mL and 701±645 pg.h/mL. The absolute bioavailability of MLT was from 1 to 37%: mean=8.6±3.9% and 16.8±12.7% for male and female subjects, respectively. Copyright © 2000 John Wiley & Sons, Ltd.

Url:

https://api.istex.fr/document/20DC831A3C9C35916E1C0A23339D91E80544CD5E/fulltext/pdf

DOI: 10.1002/1099-081X(200001)21:1<15::AID-BDD215>3.0.CO;2-H

Affiliations:

Links to Exploration step

ISTEX:20DC831A3C9C35916E1C0A23339D91E80544CD5E

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Bioavailability of melatonin in humans after day‐time administration of D7 melatonin</title>
<author><name sortKey="Fourtillan, J B" sort="Fourtillan, J B" uniqKey="Fourtillan J" first="J. B." last="Fourtillan">J. B. Fourtillan</name>
</author>
<author><name sortKey="Brisson, A M" sort="Brisson, A M" uniqKey="Brisson A" first="A. M." last="Brisson">A. M. Brisson</name>
</author>
<author><name sortKey="Gobin, P" sort="Gobin, P" uniqKey="Gobin P" first="P." last="Gobin">P. Gobin</name>
</author>
<author><name sortKey="Ingrand, I" sort="Ingrand, I" uniqKey="Ingrand I" first="I." last="Ingrand">I. Ingrand</name>
</author>
<author><name sortKey="Decourt, J Ph" sort="Decourt, J Ph" uniqKey="Decourt J" first="J. Ph." last="Decourt">J. Ph. Decourt</name>
</author>
<author><name sortKey="Girault, J" sort="Girault, J" uniqKey="Girault J" first="J." last="Girault">J. Girault</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:20DC831A3C9C35916E1C0A23339D91E80544CD5E</idno>
<date when="2000" year="2000">2000</date>
<idno type="doi">10.1002/1099-081X(200001)21:1<15::AID-BDD215>3.0.CO;2-H</idno>
<idno type="url">https://api.istex.fr/document/20DC831A3C9C35916E1C0A23339D91E80544CD5E/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000359</idno>
<idno type="wicri:Area/Istex/Curation">000280</idno>
<idno type="wicri:Area/Istex/Checkpoint">002284</idno>
<idno type="wicri:doubleKey">0142-2782:2000:Fourtillan J:bioavailability:of:melatonin</idno>
<idno type="wicri:Area/Main/Merge">002B21</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:11038434</idno>
<idno type="wicri:Area/PubMed/Corpus">000248</idno>
<idno type="wicri:Area/PubMed/Curation">000248</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000237</idno>
<idno type="wicri:Area/Ncbi/Merge">000029</idno>
<idno type="wicri:Area/Ncbi/Curation">000029</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000029</idno>
<idno type="wicri:doubleKey">0142-2782:2000:Fourtillan J:bioavailability:of:melatonin</idno>
<idno type="wicri:Area/Main/Merge">002823</idno>
<idno type="wicri:Area/Main/Curation">002A52</idno>
<idno type="wicri:Area/Main/Exploration">002A52</idno>
<idno type="wicri:Area/France/Extraction">000106</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Bioavailability of melatonin in humans after day‐time administration of D7 melatonin</title>
<author><name sortKey="Fourtillan, J B" sort="Fourtillan, J B" uniqKey="Fourtillan J" first="J. B." last="Fourtillan">J. B. Fourtillan</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>CEMAF, 6 Avenue Mozart, 86000 Poitiers</wicri:regionArea>
<placeName><region type="region" nuts="2">Aquitaine-Limousin-Poitou-Charentes</region>
<region type="old region" nuts="2">Poitou-Charentes</region>
<settlement type="city">Poitiers</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brisson, A M" sort="Brisson, A M" uniqKey="Brisson A" first="A. M." last="Brisson">A. M. Brisson</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>CEMAF, 6 Avenue Mozart, 86000 Poitiers</wicri:regionArea>
<placeName><region type="region" nuts="2">Aquitaine-Limousin-Poitou-Charentes</region>
<region type="old region" nuts="2">Poitou-Charentes</region>
<settlement type="city">Poitiers</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gobin, P" sort="Gobin, P" uniqKey="Gobin P" first="P." last="Gobin">P. Gobin</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>CEMAF, 6 Avenue Mozart, 86000 Poitiers</wicri:regionArea>
<placeName><region type="region" nuts="2">Aquitaine-Limousin-Poitou-Charentes</region>
<region type="old region" nuts="2">Poitou-Charentes</region>
<settlement type="city">Poitiers</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ingrand, I" sort="Ingrand, I" uniqKey="Ingrand I" first="I." last="Ingrand">I. Ingrand</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>CEMAF, 6 Avenue Mozart, 86000 Poitiers</wicri:regionArea>
<placeName><region type="region" nuts="2">Aquitaine-Limousin-Poitou-Charentes</region>
<region type="old region" nuts="2">Poitou-Charentes</region>
<settlement type="city">Poitiers</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Decourt, J Ph" sort="Decourt, J Ph" uniqKey="Decourt J" first="J. Ph." last="Decourt">J. Ph. Decourt</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>CEMAF, 6 Avenue Mozart, 86000 Poitiers</wicri:regionArea>
<placeName><region type="region" nuts="2">Aquitaine-Limousin-Poitou-Charentes</region>
<region type="old region" nuts="2">Poitou-Charentes</region>
<settlement type="city">Poitiers</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Girault, J" sort="Girault, J" uniqKey="Girault J" first="J." last="Girault">J. Girault</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>CEMAF, 6 Avenue Mozart, 86000 Poitiers</wicri:regionArea>
<placeName><region type="region" nuts="2">Aquitaine-Limousin-Poitou-Charentes</region>
<region type="old region" nuts="2">Poitou-Charentes</region>
<settlement type="city">Poitiers</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Biopharmaceutics & Drug Disposition</title>
<title level="j" type="abbrev">Biopharm. Drug Dispos.</title>
<idno type="ISSN">0142-2782</idno>
<idno type="eISSN">1099-081X</idno>
<imprint><publisher>John Wiley & Sons, Ltd.</publisher>
<pubPlace>Chichester, UK</pubPlace>
<date type="published" when="2000-01">2000-01</date>
<biblScope unit="volume">21</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="15">15</biblScope>
<biblScope unit="page" to="22">22</biblScope>
</imprint>
<idno type="ISSN">0142-2782</idno>
</series>
<idno type="istex">20DC831A3C9C35916E1C0A23339D91E80544CD5E</idno>
<idno type="DOI">10.1002/1099-081X(200001)21:1<15::AID-BDD215>3.0.CO;2-H</idno>
<idno type="ArticleID">BDD215</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0142-2782</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term>
<term>Adult</term>
<term>Anticonvulsants (administration & dosage)</term>
<term>Anticonvulsants (blood)</term>
<term>Anticonvulsants (pharmacokinetics)</term>
<term>Area Under Curve</term>
<term>Biological Availability</term>
<term>Cross-Over Studies</term>
<term>D7 melatonin</term>
<term>Female</term>
<term>Gas Chromatography-Mass Spectrometry</term>
<term>Humans</term>
<term>Infusions, Intravenous</term>
<term>Male</term>
<term>Melatonin (administration & dosage)</term>
<term>Melatonin (blood)</term>
<term>Melatonin (pharmacokinetics)</term>
<term>Metabolic Clearance Rate</term>
<term>Time Factors</term>
<term>bioavailability</term>
<term>pharmacokinetics</term>
<term>young healthy subjects</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anticonvulsants</term>
<term>Melatonin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Anticonvulsants</term>
<term>Melatonin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Anticonvulsants</term>
<term>Melatonin</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term>
<term>Adult</term>
<term>Area Under Curve</term>
<term>Biological Availability</term>
<term>Cross-Over Studies</term>
<term>Female</term>
<term>Gas Chromatography-Mass Spectrometry</term>
<term>Humans</term>
<term>Infusions, Intravenous</term>
<term>Male</term>
<term>Metabolic Clearance Rate</term>
<term>Time Factors</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Absolute bioavailability of the neurohormone melatonin (MLT) was studied in 12 young healthy volunteers (six males, six females) after administration at midday, on two separate occasions, of 23 µg by intravenous (i.v.) infusion and 250 µg by oral solution of D7 MLT, a molecule in which seven deuterium atoms replace seven hydrogen atoms. Exogenous (D7) and endogenous (D0) MLT were quantified simultaneously but separately by a highly specific assay: gas chromatography/negative ion chemical ionization mass spectrometry, developed in our laboratory, which enabled us to go down to 0.5 pg/mL in plasma samples. After i.v. administration, the maximum plasma concentration (Cmax) and the area under the plasma concentration–time curve (AUC) values were significantly different in male and female subjects, but there was no significant gender difference in total body clearance normalized to body weight: 1.27±0.20 L/h/kg and 1.18±0.22 L/h/kg for males and females, respectively. The apparent terminal half‐life (t 1/2 z) values were 36±2 and 41±10 min, respectively. After oral administration, pharmacokinetic parameters used to quantify bioavailability were near three‐fold greater in female subjects than in males, with large inter‐individual variations. The maximum plasma MLT concentration Cmax±S.D. was found at 243.7±124.6 pg/mL and 623.6±575.1 pg/mL for male and female subjects respectively, while the mean values for AUCs were 236±107 pg.h/mL and 701±645 pg.h/mL. The absolute bioavailability of MLT was from 1 to 37%: mean=8.6±3.9% and 16.8±12.7% for male and female subjects, respectively. Copyright © 2000 John Wiley & Sons, Ltd.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Aquitaine-Limousin-Poitou-Charentes</li>
<li>Poitou-Charentes</li>
</region>
<settlement><li>Poitiers</li>
</settlement>
</list>
<tree><country name="France"><region name="Aquitaine-Limousin-Poitou-Charentes"><name sortKey="Fourtillan, J B" sort="Fourtillan, J B" uniqKey="Fourtillan J" first="J. B." last="Fourtillan">J. B. Fourtillan</name>
</region>
<name sortKey="Brisson, A M" sort="Brisson, A M" uniqKey="Brisson A" first="A. M." last="Brisson">A. M. Brisson</name>
<name sortKey="Decourt, J Ph" sort="Decourt, J Ph" uniqKey="Decourt J" first="J. Ph." last="Decourt">J. Ph. Decourt</name>
<name sortKey="Girault, J" sort="Girault, J" uniqKey="Girault J" first="J." last="Girault">J. Girault</name>
<name sortKey="Gobin, P" sort="Gobin, P" uniqKey="Gobin P" first="P." last="Gobin">P. Gobin</name>
<name sortKey="Ingrand, I" sort="Ingrand, I" uniqKey="Ingrand I" first="I." last="Ingrand">I. Ingrand</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/MozartV1/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000106 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000106 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Musique
   |area=    MozartV1
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     ISTEX:20DC831A3C9C35916E1C0A23339D91E80544CD5E
   |texte=   Bioavailability of melatonin in humans after day‐time administration of D7 melatonin
}}

This area was generated with Dilib version V0.6.20.
Data generation: Sun Apr 10 15:06:14 2016. Site generation: Tue Feb 7 15:40:35 2023

Serveur d'exploration sur Mozart

Bioavailability of melatonin in humans after day‐time administration of D7 melatonin

Bioavailability of melatonin in humans after day‐time administration of D7 melatonin

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration sur Mozart
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.